Objective: To assess the efficacy of ritonavir-boosted protease inhibitor monotherapy.
Design and methods: Systematic review of all protease inhibitor-monotherapy studies …

Background The unparalleled success of combination antiretroviral therapy (cART) is based
on the combination of three drugs from two classes. There is insufficient evidence whether …

Abstract Antiretroviral-naive HIV-1-infected volunteers received zidovudine/lamivudine plus
either lopinavir/ritonavir (n= 104) or efavirenz (n= 51). Lopinavir/ritonavir-treated subjects …

Background Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV)
alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)–sparing …

Current US guidelines for initial therapy of HIV type-1 (HIV-1) infection recommend daily,
lifelong treatment with a combination of three antiretroviral drugs consisting of two …

Background. In recent studies, subjects who had achieved suppression of the human
immunodeficiency virus (HIV) RNA level while receiving an initial 3-drug antiretroviral …

Background The aim of the present study was to determine appropriate tenofovir-based
regimens meriting evaluation in large-scale randomized trials among sub-Saharan African …

The report in this issue of Clinical Infectious Diseases by Sungkanuparph et al.[1] from
Thailand provides important confirmation of a long-standing concern regarding failure of …

Previous studies have demonstrated that lopinavir/ritonavir monotherapy maintained plasma
HIV-1 RNA suppression in a large proportion of antiretroviral naive subjects. However, more …

Despite the remarkable success of combination antiretroviral therapy, usually including the
association of three antiretroviral drugs selected from two different classes, the possibility of …